HALOZYME THERAPEUTICS INC
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the fiscal quarter ended ended March 31, 2024, the following officers adopted or terminated any Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K) as noted in the table below.
| Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name and Title | Action | Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares To Be Sold | Expiration Date |
| Helen Torley | Termination | 1/30/2024 | X | 500,000 | Terminated(1) | |
| President and Chief Executive Officer | ||||||
| Helen Torley | Adoption | 3/22/2024 | X | 110,000 | (2) | The earlier of 02/13/2025 or date all shares are sold |
| President and Chief Executive Officer | ||||||
| Nicole LaBrosse | Adoption | 3/22/2024 | X | 35,000 | (2) | The earlier of 06/25/2025 or date all shares are sold |
| Senior Vice President and Chief Financial Officer | ||||||
- Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
** Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
(1)The duration of the trading arrangement was until May 30, 2024, or earlier if all transaction under the trading arrangement had been completed. At the time of termination, no shares had been sold under the trading arrangement.
(2)Represents a sale of common shares acquired upon exercise of stock options with ten-year term expiring in 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.